Research programme: ATPase inhibitors - Sigma Tau
Latest Information Update: 08 Aug 2007
At a glance
- Originator sigma-tau SpA
- Mechanism of Action Adenosine triphosphatase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 03 Feb 1998 New profile
- 03 Feb 1998 Preclinical development for Hypertension in Italy (Unknown route)